216658-62-7

Usage

Physical state

Colorless to pale yellow liquid

Odor

Strong, sweet

Usage

Intermediate and reagent in the production of various industrial and pharmaceutical compounds

Application

Organic synthesis, building block in the production of polymers and plastics

Toxicity

Mildly toxic

Safety precautions

Handle with care, can cause skin and eye irritation upon contact

Protective measures

Use proper protective equipment and follow safety guidelines when handling

Upstream product

• 82657-69-0 (3-ethylphenyl)methanol 
• 619-20-5 m-ethylbenzoic acid 
• 34246-54-3 3-ethyl-benzaldehyde 
• 15852-73-0 (3-Bromophenyl)methanol 

Downstream Products

• 1754-69-4 Dimethyl-<3-ethyl-benzyl>-carbinol 
• 216658-92-3 1-Bromomethyl-3-n-propylbenzene 
• 1195786-93-6 C₂₉H₃₉ClO₅S 
• 1195787-22-4 C₃₇H₄₇ClO₅S 
• 1444010-83-6 {(1R)-2-(3-ethylphenyl)-1-[(4-oxo-4-phenylbutanoyl)amino]ethyl}boronic acid (+)-pinane-2,3-diyl diester 
• 1444009-53-3 {(1R)-2-(3-ethylphenyl)-1-[(4-oxo-4-phenylbutanoyl)amino]ethyl}boronic acid 
• 1444010-84-7 [(1R)-1-[(4-biphenyl-4-yl-4-oxobutanoyl)amino]-2-(3-ethylphenyl)ethyl]boronic acid (+)-pinane-2,3-diyl diester 
• 1444009-64-6 [(1R)-1-[(4-biphenyl-4-yl-4-oxobutanoyl)amino]-2-(3-ethylphenyl)ethyl]boronic acid 
• 1444010-71-2 [(1S)-1-chloro-2-(3-ethylphenyl)ethyl]boronic acid (+)-pinane-2,3-diyl diester 
• 1444010-72-3 N-((R)-2-(3-ethylphenyl)-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)ethyl)-1,1,1-trimethyl-N-(trimethylsilyl)silanamine 
• 1444009-35-1 [(1R)-1-amino-2-(3-ethylphenyl)ethyl]boronic acid (+)-pinane-2,3-diyl diester trifluoroacetate 
• 1444010-69-8 2-(3-ethylbenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1444010-70-1 (3aS,4S,6S,7aR)-2-(3-ethylbenzyl)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole 

Relevant academic research and scientific papers

IMMUNOPROTEASOME INHIBITORS

Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Attenuation of London Dispersion in Dichloromethane Solutions

London dispersion constitutes one of the fundamental interaction forces between atoms and between molecules. While modern computational methods have been developed to describe the strength of dispersive interactions in the gas phase properly, the importance of inter-and intramolecular dispersion in solution remains yet to be fully understood because experimental data are still sparse in that regard. We herein report a detailed experimental and computational study of the contribution of London dispersion to the bond dissociation of proton-bound dimers, both in the gas phase and in dichloromethane solution, showing that attenuation of inter-and intramolecular dispersive interaction by solvent is large (about 70% in dichloromethane), but not complete, and that current state-of-The-Art implicit solvent models employed in quantum-mechanical computational studies treat London dispersion poorly, at least for this model system.

BORONIC ACID DERIVATIVES

Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmue disorder or hematological malignancies.

BORONIC ACID DERIVATIVES

Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmue disorder or hematological malignancies.

ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS

The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.

THERAPEUTIC SUBSTITUTED CYCLOPENTANES

Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

Uracil compounds as P2-purinoreceptor 7-transmembrane G-protein coupled receptor antagonists

Compounds of formula I or salts thereof where for example Y is a group of the formula (i) and R1is a group of formula (ii) are provided along with compositions containing them and processes for their preparation. The compounds are P2-purinoreceptor 7-transmembrane G-protein coupled receptor antagonists, and are useful in the treatment of inflammatory conditions.

2,4-Dithi(oxo)-pyrimidin-5-yl compounds bearing a tricyclic substituent useful as P2 purinoceptor antagonists

PCT No. PCT/SE98/01240 Sec. 371 Date Sep. 30, 1998 Sec. 102(e) Date Sep. 30, 1998 PCT Filed Jun. 25, 1998 PCT Pub. No. WO99/02501 PCT Pub. Date Jan. 21, 1999The invention relates to new pharmaceutically active compounds which are P2-purinoceptor 7-transmembrane (TM) G-protein coupled receptor antagonists, compositions containing them and processes for their preparation.